A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial.
John Sarantopoulos
No relevant relationships to disclose
Long H. Dang
No relevant relationships to disclose
Richard C. Lauer
No relevant relationships to disclose
Alexander Starodub
No relevant relationships to disclose
Ralph J. Hauke
No relevant relationships to disclose
Matt D. Galsky
No relevant relationships to disclose
Kathryn A. Bylow
No relevant relationships to disclose
Charles Lance Cowey
No relevant relationships to disclose
David C. Bibby
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Gabriel Kremmidiotis
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Elizabeth E. Doolin
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Tina C. Lavranos
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Jose Luis Iglesias
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Guru Sonpavde
No relevant relationships to disclose
Theodore Logan
No relevant relationships to disclose
Noah M. Hahn
No relevant relationships to disclose
Christopher Sweeney
Consultant or Advisory Role - Bionomics
Thomas E. Hutson
No relevant relationships to disclose